Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

argenx (ARGX) halted its Phase 3 UNITY trial for efgartigimod in Sjögren’s disease after the IDMC recommended stopping due to futility. The trial failed to meet its primary endpoint, though safety results aligned with expectations. The company will analyze data for future research. Efgartigimod is approved for other autoimmune diseases.

argenx reported positive Phase 2 results for FB102 in celiac disease, meeting the primary endpoint. The company plans to advance to Phase 3. According to the company, no new safety signals were observed.

argenx SE (ARGX) will halt its Phase 3 UNITY trial of efgartigimod SC in Sjögren's disease due to futility, following an IDMC recommendation. The company reports safety data were consistent with prior findings. This marks a setback in argenx's efforts to expand the drug's use in autoimmune diseases.

argenx reported positive Phase 2 results for FB102, a CD122 inhibitor, in celiac disease. The study met its primary endpoint (p=0.0176) and showed efficacy across multiple measures. The company plans to advance FB102 into Phase 3 development. FB102 is also being evaluated for other autoimmune diseases.

argenx (ARGX) halted its Phase 3 UNITY study of efgartigimod SC for Sjögren's disease after an IDMC recommended stopping due to futility. The study failed to meet its primary endpoint, though safety data were consistent with expectations. argenx plans to analyze the data further and share insights with the Sjögren's community.

Halozyme won a Dutch court order against Merck, halting the sale and production of Keytruda SC in eight European markets. The ruling found Merck infringed Halozyme's patent for under-the-skin drug delivery. Merck plans to evaluate next steps and disputes the decision. Halozyme has also sued Merck in the U.S. and Germany.